PepGen (PEPG) Cash from Investing Activities (2021 - 2026)
PepGen (PEPG) reported Cash from Investing Activities of -$1.5 million for Q1 2026, down 108.51% on a YoY basis from $17.1 million in Q1 2025, and up 97.8% sequentially from -$66.2 million in Q4 2025.
PepGen (PEPG) Cash from Investing Activities (2021 - 2026) Analysis & Trends
PepGen (PEPG) has 6 years of Cash from Investing Activities data on file, last reported at -$1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 108.51% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$33.8 million (down 266.78% YoY), and the FY2025 full-year result was -$15.2 million, up 59.55% from the prior year.
- Cash from Investing Activities grew to -$1.5 million in Q1 2026, from -$66.2 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $26.5 million in Q4 2024 to a low of -$66.2 million in Q4 2025.
- A 5-year average of -$5.3 million and a median of -$1.0 million in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities tumbled 5127.35% in 2024 and soared 14312.78% in 2025, its largest moves.
- Tracing PEPG's Cash from Investing Activities over 5 years: stood at -$1.1 million in 2022, then tumbled by 2584.94% to -$29.6 million in 2023, then surged by 189.57% to $26.5 million in 2024, then tumbled by 349.97% to -$66.2 million in 2025, then surged by 97.8% to -$1.5 million in 2026.
- Business Quant data shows PEPG's Cash from Investing Activities at -$1.5 million in Q1 2026, -$66.2 million in Q4 2025, and $18.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -45.51 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 178,242.27 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 172.62 Mn |
| 10 | PepGen | 145.09 Mn | 145.09 Mn | - | -1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.46 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | -66.24 Mn |
| Dec 31, 2025 | -66.24 Mn |
| Sep 30, 2025 | 18.90 Mn |
| Sep 30, 2025 | 18.90 Mn |
| Jun 30, 2025 | 14.96 Mn |
| Jun 30, 2025 | 14.96 Mn |
| Mar 31, 2025 | 17.15 Mn |
| Mar 31, 2025 | 17.15 Mn |
| Dec 31, 2024 | 26.50 Mn |
| Dec 31, 2024 | 26.50 Mn |
| Sep 30, 2024 | -133,000.00 |
| Sep 30, 2024 | -133,000.00 |
| Jun 30, 2024 | -52.74 Mn |
| Jun 30, 2024 | -52.74 Mn |
| Mar 31, 2024 | -11.29 Mn |
| Mar 31, 2024 | -11.29 Mn |
| Dec 31, 2023 | -29.59 Mn |
| Dec 31, 2023 | -29.59 Mn |